314 related articles for article (PubMed ID: 22056610)
1. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
[TBL] [Abstract][Full Text] [Related]
2. Long-term nonsense suppression therapy moderates MPS I-H disease progression.
Gunn G; Dai Y; Du M; Belakhov V; Kandasamy J; Schoeb TR; Baasov T; Bedwell DM; Keeling KM
Mol Genet Metab; 2014 Mar; 111(3):374-381. PubMed ID: 24411223
[TBL] [Abstract][Full Text] [Related]
3. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation.
Wang D; Shukla C; Liu X; Schoeb TR; Clarke LA; Bedwell DM; Keeling KM
Mol Genet Metab; 2010 Jan; 99(1):62-71. PubMed ID: 19751987
[TBL] [Abstract][Full Text] [Related]
4. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.
Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM
Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948
[TBL] [Abstract][Full Text] [Related]
5. Ataluren suppresses a premature termination codon in an MPS I-H mouse.
Wang D; Xue X; Gunn G; Du M; Siddiqui A; Weetall M; Keeling KM
J Mol Med (Berl); 2022 Aug; 100(8):1223-1235. PubMed ID: 35857082
[TBL] [Abstract][Full Text] [Related]
6. Effects of gentamicin inducing readthrough premature stop Codons: A study of alpha-L-iduronidase nonsense variants in COS-7 Cells.
Ngiwsara L; Sawangareetrakul P; Wattanasirichaigoon D; Tim-Aroon T; Dejkhamron P; Champattanachai V; Ketudat-Cairns JR; Svasti J
Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):147-154. PubMed ID: 36332477
[TBL] [Abstract][Full Text] [Related]
7. Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome).
Siddiqui A; Dundar H; Sharma J; Kaczmarczyk A; Echols J; Dai Y; Sun CR; Du M; Liu Z; Zhao R; Wood T; Sanders S; Rasmussen L; Bostwick JR; Augelli-Szafran C; Suto M; Rowe SM; Bedwell DM; Keeling KM
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901952
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.
Keeling KM; Wang D; Dai Y; Murugesan S; Chenna B; Clark J; Belakhov V; Kandasamy J; Velu SE; Baasov T; Bedwell DM
PLoS One; 2013; 8(4):e60478. PubMed ID: 23593225
[TBL] [Abstract][Full Text] [Related]
9. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
Keeling KM; Bedwell DM
J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912
[TBL] [Abstract][Full Text] [Related]
10. alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients.
Hein LK; Bawden M; Muller VJ; Sillence D; Hopwood JJ; Brooks DA
J Mol Biol; 2004 Apr; 338(3):453-62. PubMed ID: 15081804
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the MPS I-H knock-in mouse reveals increased femoral biomechanical integrity with compromised material strength and altered bone geometry.
Oestreich AK; Garcia MR; Yao X; Pfeiffer FM; Nobakhti S; Shefelbine SJ; Wang Y; Brodeur AC; Phillips CL
Mol Genet Metab Rep; 2015 Dec; 5():3-11. PubMed ID: 28649535
[TBL] [Abstract][Full Text] [Related]
12. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
[TBL] [Abstract][Full Text] [Related]
13. Evidence that glycosaminoglycan storage and collagen deposition in the cauda epididymidis does not impair sperm viability in the Mucopolysaccharidosis type I mouse model.
do Nascimento CC; Aguiar O; Viana GM; D Almeida V
Reprod Fertil Dev; 2020 Feb; 32(3):304-312. PubMed ID: 31679559
[TBL] [Abstract][Full Text] [Related]
14. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.
Nudelman I; Glikin D; Smolkin B; Hainrichson M; Belakhov V; Baasov T
Bioorg Med Chem; 2010 Jun; 18(11):3735-46. PubMed ID: 20409719
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic characterisation of the Mucopolysaccharidosis Type I (MPSI) Idua-W392X mouse model reveals increased anxiety-related traits in female mice.
Andreou T; Ishikawa-Learmonth Y; Bigger BW
Mol Genet Metab; 2023 Aug; 139(4):107651. PubMed ID: 37473537
[TBL] [Abstract][Full Text] [Related]
16. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
Ou L; Przybilla MJ; Koniar B; Whitley CB
Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
[TBL] [Abstract][Full Text] [Related]
17. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
[TBL] [Abstract][Full Text] [Related]
18. Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.
Yogalingam G; Guo XH; Muller VJ; Brooks DA; Clements PR; Kakkis ED; Hopwood JJ
Hum Mutat; 2004 Sep; 24(3):199-207. PubMed ID: 15300847
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Chromenopyridine Derivatives as Readthrough-Inducing Drugs.
Kawai S; Takashima S; Ando M; Shintaku S; Takeda S; Otake K; Ito Y; Fukui M; Yamamoto M; Shoji Y; Shirahase H; Kitao T
Chem Pharm Bull (Tokyo); 2023; 71(12):859-878. PubMed ID: 38044139
[TBL] [Abstract][Full Text] [Related]
20. An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life.
Kingma SD; Langereis EJ; de Klerk CM; Zoetekouw L; Wagemans T; IJlst L; Wanders RJ; Wijburg FA; van Vlies N
Orphanet J Rare Dis; 2013 Jul; 8():99. PubMed ID: 23837464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
